{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:53Z","timestamp":1794047573920,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is widely used for hematologic malignancies, yet balancing graft-versus-host disease (GVHD) prophylaxis and immune reconstitution remains challenging. In this prospective, nonrandomized study, we compared a higher-dose anti-CD25 strategy that omitted methotrexate with a conventional lower-dose anti-CD25 regimen that included methotrexate. Lower cumulative anti-thymocyte globulin exposure was observed in the higher-dose group. From May 2022 to January 2025, 276 patients were enrolled (lower-dose group, n=149; higher-dose group, n=127). After a median follow-up of 28.4 months, the higher-dose strategy was associated with a lower 100-day cumulative incidence of grade III\u2013IV acute GVHD (7.9% vs. 17.5%; adjusted subdistribution hazard ratio, 0.39; 95% confidence interval, 0.18\u20130.88; p=0.022) and improved graft-versus-host diseasefree, relapse-free survival (GRFS) (adjusted hazard ratio, 0.59; 95% confidence interval, 0.43\u20130.83; p=0.002). Chronic GVHD, overall survival, disease-free survival, relapse, and non-relapse mortality did not differ significantly between groups. Exploratory immune monitoring showed transiently lower CD4+ T-cell counts at day +30 in the higherdose group, whereas longitudinal immune reconstitution trajectories and infectious complications were broadly comparable. These findings suggest that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200060184.<\/jats:p>","DOI":"10.3324\/haematol.2026.301352","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:21:12Z","timestamp":1790842872000},"source":"Crossref","is-referenced-by-count":0,"title":["CD25-based graft-&lt;i&gt;versus&lt;\/i&gt;-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies"],"prefix":"10.3324","author":[{"given":"Qianlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiena","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,10,1]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2026.301352\/80958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14455\/80958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:15:40Z","timestamp":1794046540000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2026.301352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.301352","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}